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Abstract
Background: Pancreatic ductal adenocarcinoma shows a distinct apoptosis resistance, which contributes significantly 
to the aggressive nature of this tumor and constrains the effectiveness of new therapeutic strategies. Apoptosis 
resistance is determined by the net balance of the cells pro-and anti-apoptotic "control mechanisms". Numerous 
dysregulated anti-apoptotic genes have been identified in pancreatic cancer and seem to contribute to the high anti-
apoptotic buffering capacity. We aimed to compare the benefit of simultaneous gene silencing (SGS) of several 
candidate genes with conventional gene silencing of single genes.
Methods: From literature search we identified the anti-apoptotic genes XIAP, Survivin and Bcl-2 as commonly 
upregulated in pancreatic cancer. We performed SGS and silencing of single candidate genes using siRNA molecules in 
two pancreatic cancer cell lines. Effectiveness of SGS was assessed by qRT-PCR and western blotting. Apoptosis 
induction was measured by flow cytometry and caspase activation.
Results: Simultaneous gene silencing reduced expression of the three target genes effectively. Compared to silencing 
of a single target or control, SGS of these genes resulted in a significant higher induction of apoptosis in pancreatic 
cancer cells.
Conclusions: In the present study we performed a subliminal silencing of different anti-apoptotic target genes 
simultaneously. Compared to silencing of single target genes, SGS had a significant higher impact on apoptosis 
induction in pancreatic cancer cells. Thereby, we give further evidence for the concept of an anti-apoptotic buffering 
capacity of pancreatic cancer cells.
Background
An important feature of oncogenesis is the alteration of
cell signaling pathways, resulting in certain cancer phe-
notypes [1]. Pancreatic ductal adenocarcinoma (PDAC) is
an extremely aggressive tumor that ranks eighth among
the most common cancers in the Western world [2].
Recently, comprehensive analysis of the genome and
the transcriptome of pancreatic tumors demonstrated the
importance of the apoptosis pathway in the pathophysiol-
ogy of pancreatic cancers [3,4]. Clinicopathologically,
apoptosis resistance contributes to the tumor's poor
response to chemotherapy, ionizing radiation and immu-
notherapy [5] and affects the metastasizing capacity and
growth rate of the tumor [6,7]. Apoptosis resistance
therefore seems to be the hallmark of cancer that largely
accounts for the aggressive nature of pancreatic cancer.
Two distinct pathways regulate Apoptosis. The 'intrin-
sic' pathway is the primary death program responsive to
different cell stress stimuli, with the mitochondrion as the
central conduit. The 'extrinsic' cell death pathway is acti-
vated through death receptors. Many physiological con-
trol points protect the cell from inappropriate apoptosis
induction [8]. The net balance of all pro-and anti-apop-
totic "control mechanisms" determines the apoptotic
threshold of the cell. Apoptosis occurs when the pro-
apoptotic load of the cell exceeds its anti-apoptotic buff-
ering capacity [9].
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Because of its clinical importance, the re-engagement
of the disrupted apoptosis program in pancreatic cancer
offers a compelling general strategy for effective and
tumor-cell-specific cancer therapy [3]. Previous studies
targeting single apoptosis-associated genes in pancreatic
cancer have shown encouraging results [10,11].
However, targeting different apoptosis-associated
genes simultaneously seems even more promising.
First, pancreatic cancer displays a large number of dys-
regulations within the cell death signaling pathway,
resulting in a high anti-apoptotic buffering capacity
[8,12]. Secondly, the pathway is generally characterized
by redundancy that compensates for perturbations affect-
ing individual components [9].
The aim of this study was to identify important dysreg-
ulated signaling interfaces of the apoptosis pathway and
to test whether simultaneous gene silencing (SGS) of
those candidate genes had a synergistic effect on the
apoptotic threshold of tumor cells in vitro. Bcl-2, XIAP
and Survivin were identified as overexpressed, synergistic
and anti-apoptotic members of the pathway by literature
search [11,13]. We performed SGS in two cell lines,
MiaPaCa-2 and AsPC-1, which displayed slightly differ-
ent expression of the target genes. Effectiveness of SGS
was assessed by qRT-PCR and western blotting. SGS
reduced the apoptotic threshold of both cell lines signifi-
cantly as measured by flow cytometry and caspase activa-
tion. Based on our results we conclude that SGS is an
effective method for re-sensitizing pancreatic cancer cells
towards apoptosis.
Methods
Identification of apoptosis-associated genes
Keywords for the search were "apoptosis", "cell death",
"cell death pathway", "cell death receptor" together with
the term "pancreatic carcinoma" or "pancreatic cancer".
Genes were considered if dysregulation was demon-
strated on the level of the transcriptome and the pro-
teome. The literature search comprised publications until
October 2008.
Cell culture, transfection conditions and simultaneous 
gene silencing assay
The MiaPaCa-2 cell line (ATCC: CRL-1420), derived
from a primary pancreatic carcinoma, was used for this
study. Cells were grown in DMEM with high glucose, 1.5
g/l sodium bicarbonate and 4 mM GlutaMAX (Invitro-
gen, Karlsruhe, Germany) with 10% FCS and 2.5% horse
serum. We also used the AsPC-1 cell line (ATCC: CRL-
1682), derived from malignant ascites. Cells were grown
in RPMI-1640 medium with 2 mM GlutaMAX, 1 mM
sodium pyruvate, 4.5 g/l glucose (Invitrogen, Karlsruhe,
Germany) and 10% FCS. Both cell lines were cultured in a
humidified atmosphere containing 5% CO2 at 37°C. Next,
5 × 104  cells were transfected using Oligofectamine
(Invitrogen GmbH, Karlsruhe, Germany). Target sense
sequences that effectively mediated silencing were as fol-
lowed:  Bcl-2  [14]: GUACAUCCAUUAUAAGCUG
(NCBI probe ID: Pr196034.1), XIAP [15]: GUGGUAGU-
CCUGUUUCAGC,  Survivin: GAAUUUGAGGAAAC
UGCGA [16] (all from MWG Biotech, Ebersberg, Ger-
many). As negative control, we used siRNA against Firefly
Luciferase (CGUACGCGGAAUACUUCGA), the All-
stars siRNA (Qiagen) and carrier solution. A total of
50,000 cells/well were single-transfected with 0.046 nM
of two negative controls (nonsense siRNA); one group
was treated with vehicle only. For the SGS, cells were co-
transfected with 0.015 nM of each of the three target
genes. Additional controls were performed using single
transfection of the different target genes, either with low-
dose siRNA (0.015 nM) or standard-dose siRNA (0.046
nM). The low-dose single transfection (lowST) was
undertaken with 0.015 nM Bcl-2, Survivin or XIAP
siRNA, each with 0.03 nM of nonsense siRNA to exclude
bias caused by the absolute amount of siRNA. Standard-
dose single transfection (ST) was undertaken with 0.046
nM of the correspondent target gene. Cells were cultured
for 72 h. At the end of incubation, all cells were harvested.
After treatment of the cells, flow cytometry and a caspase
activity assay were performed to determine the apoptosis
rate. Silencing was confirmed by western blot.
Reverse Transcription Polymerase Reaction (RT-PCR)
For quantitative RT-PCR, total RNA was isolated using
the RNeasy Mini Kit (Qiagen, Hilden, Germany), cDNA
was synthesized using random primer and SuperScript II
(Invitrogen GmbH, Karlsruhe, Germany). The genes were
amplified with the Power SybrGreen PCR Master Mix
according to the manufacturer's instructions. Gene
expression was quantified by the comparative cT-
Method, normalizing cT-values to a housekeeping gene
(β-Actin) and calculating the relative expression values.
Primers used in this study are shown in table 1.
Western Blotting
Cells were lysed with LDS sample buffer (Invitrogen,
Karlsruhe, Germany). Proteins were electrophoresed
under reducing conditions on 4-12% acrylamide gels
(Invitrogen, Karlsruhe, Germany) and then transferred to
a nitrocellulose membrane (Hybond ECL, GE Healthcare,
Munich, Germany). To block nonspecific binding, the
membrane was incubated overnight in TBS-T 0.1% con-
taining 5% BSA for Bcl-2 or 5% milk for Survivin and
XIAP at 4°C. Subsequently, the membrane was either
incubated with an antibody to Survivin (1:1000, NB 500-
201, Novus Biologicals, Acris Antibodies, Hiddenhausen,
Germany), Bcl-2 (1:200, sc-509, Santa Cruz, Heidelberg,
Germany),  XIAP  (1:500, 610716, Becton Dickinson,Rückert et al. BMC Cancer 2010, 10:379
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Heidelberg, Germany) or GAPDH (1:5000, ab 8245-100,
abcam, Cambridge, UK) in TBS-T 0.1% with blocking as
mentioned above for 1 h. After washing in TBS, the pro-
tein was visualized using the ECL detection kit (GE
Healthcare, Munich, Germany) with a peroxidase-labeled
anti-mouse antibody (1:25,000, NIF825, GE Healthcare,
Munich, Germany) or an anti-rabbit antibody (1:5,000,
NIF824, GE Healthcare, Munich, Germany).
For a loading control, the membranes were blocked
again and probed with monoclonal antibodies for
GAPDH according to standard protocols. Protein expres-
sion was determined as the ratio of target gene staining
intensity to GAPDH staining intensity using AIDA evalu-
ation software (Raytest, Straubenhardt, Germany). To
compare blots of the different transfections, staining
intensities of the different transfections were normalized
to the SGS treated group. All blots were done in triplicate.
Determination of cell death and apoptosis
Cells were harvested 72 h after transfection. Cells were
trypsinized and treated with 50 μg/mL propidium iodide
and Annexin V-FITC (Becton Dickinson, Heidelberg,
Germany). The cells were analyzed and quantified with
flow cytometry (10,000 cells analyzed) (FACS Calibur;
Becton Dickinson, Heidelberg, Germany). For analysis of
Apoptosis we counted Annexin-positive cells of the
upper and lower right quadrants. For further statistical
analysis, we formed a quotient with untreated cells for
every group. Caspase 3 and 7 activity was measured on
deep frozen cell pellets containing 20,000 cells harvested
72 h after transfection using the Caspase Glo-Assay (Pro-
mega, Mannheim, Germany) according to the manufac-
turer's instructions. Results of the caspase assay were also
normalized to untreated cells.
Statistical analysis
For statistical analysis, the t test and the Mann-Whitney
U test of "SPSS 13.0" for Windows were used.
Results
Selection of target genes
A comprehensive literature search identified several dys-
regulated apoptosis-associated genes in pancreatic can-
cer. The ideal characteristics of our candidate genes for
SGS were upregulation at the RNA and protein levels and
synergistic anti-apoptotic action in the course of the cell
death pathway. Because the intrinsic pathway has a cen-
tral role in pancreatic cancer cells we only considered
members of this pathway for our study. XIAP [13,17,18],
Survivin [11,13,19] and Bcl-2 [20-22] met all these crite-
ria and are characterized as upregulated in PDAC cell
lines as well as native tumor tissue.
Simultaneous gene-silencing of Bcl-2, Survivin and XIAP
To elucidate the effect of simultaneous gene-silencing in
pancreatic cancer, we established a protocol for simulta-
neous post transcriptional gene silencing using siRNA.
For SGS we chose the human pancreatic cancer cell line
MiaPaCa-2, which expresses XIAP, Bcl-2 and Survivin
and AsPC-1 cells, which express XIAP and Survivin (Fig-
ure 1; Additional file 1). We determined the maximal
dose without toxic effects to be 0.046 nM siRNA per
50,000 cells (data not shown). Using qRT-PCR and west-
ern blot we verified the target genes to be silenced at the
mRNA and protein levels in transfected cells. QRT-PCR
showed the expression of all three target genes in SGS,
lowST and ST to be strongly reduced compared with con-
trols. We validated knock-down of the target genes by
SGS in western blot.
The reduction of Bcl-2, XIAP and Survivin protein
expression by SGS was statistically significant as com-
pared to controls in MiaPaCa-2 cells (p < 0.05). We also
found a statistically significant reduction of the expres-
sion of XIAP and Survivin by SGS in AsPC-1 cells in
western blot (p < 0.05) (Figure 1).
LowST and ST transfection also resulted in a significant
reduction of protein expression of the target genes in
both cell lines in western blot.
To examine off-target effects of gene-silencing in our
cells, we performed a qRT-PCR of Interferon beta and
STAT1. The genes showed no differential expression in
any of our transfections (Additional file 2).
Effect of SGS on the apoptotic threshold in pancreatic 
cancer cells
To determine the optimal time point for harvesting and
to show that all groups displayed a similar kinetic
response to transfection, a dynamic measurement of cas-
Table 1: Primers used for RT-PCR in the present study
Primer Forward reverse
β-Actin AAGCCACCCCACTTCTCTCTAA AATGCTATCACCTCCCCTGTGT
Bcl-2 ATGTGTGTGGAGAGCGTCAA ACAGTTCCACAAAGGCATCC
Survivin GTTGCGCTTTCCTTTCTGTC TCTCCGCAGTTTCCTCAAAT
XIAP CACTTGAGGTTCTGGTTGCAG TGCAAAGCTTCTCCTCTTGC
STAT1 AATGCTGGCACCAGAACGAA ATCACCACAACGGGCAGAGA
IFNB GCAATTGAATGGGAGGCTTG GGCGTCCTCCTTCTGGAACTRückert et al. BMC Cancer 2010, 10:379
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pases 3 and 7 activity was conducted every 12 hours after
transfection; activation was maximal after 72 h (Addi-
tional file 1).
Simultaneous silenced MiaPaCa-2 cells showed a 3.43-
fold increase in the rate of apoptotic cells in flow cytome-
try compared to controls (12.81 ± 2.09 vs. 3.73 ± 0.55; p <
0.001). Standard single transfected cells (ST) of the Sur-
vivin group also resulted in a significantly elevated apop-
tosis rate compared to the controls (7.77 ± 1.82 vs. 3.73 ±
0.55; p = 0.043) (Figure 2A, E).
Accordingly, caspases 3 and 7 showed significant activ-
ity in the SGS group in MiaPaCa-2 cells compared to con-
trols (9.95 ± 1.78 vs. 2.15 ± 0.27; p  = 0.002). Single
transfection of Survivin led to a significant caspase acti-
vation in the lowST (3.77 ± 0.56; p = 0.015) as well as in
the ST group (8.4 ± 3.10; p = 0.007).
Moreover, transfection of XIAP led to significant cas-
pase activation in the ST group (7.0 ± 0.35; p = 0.011)
(Figure 2C) (Table 2).
In AsPC-1 cells, SGS resulted in a 2.01-fold increase in
the rate of apoptotic cells compared to controls as mea-
sured by flow cytometry (4.49 ± 0.30 vs. 2.23 ± 0.22; p =
0.009). Survivin showed increased numbers of apoptotic
cells in flow cytometry in the lowST (3.17 ± 0.20; p =
0.0028) as well as in the ST group (3.94 ± 0.27; p = 0.009).
ST of XIAP led to a significantly elevated apoptosis rate
compared to controls (3.19 ± 0.11; p = 0.009) (Figure 2B,
E).
Analogously, activation of caspases 3 and 7 in AsPC-1
cells was significantly elevated in the SGS group (9.90
±1.92 vs. 1.17 ± 0.31; p = 0.021). However, none of the
control groups showed statistically significant activation,
although there was a tendency in the XIAP (2.55 ± 0.41)
and Survivin ST groups (3.27 ± 0.96) (Figure 2D) (Table
2).
Corresponding to the higher apoptosis rate we saw a
reduced number of viable cells in the SGS group in both
cell lines, with a 6.7-fold reduction of vital MiaPaCa-2
cells (p = 0.021) and a 4.75-fold reduction in AsPC-1 cells
(p = 0.05) as compared to controls (Table 2).
Discussion
Apoptosis resistance in pancreatic cancer is highly rele-
vant for the aggressive nature of the disease. Previous
studies in pancreatic cancer have described multiple
defects in apoptosis signaling at different levels of the
Figure 2 Effect of SGS on apoptosis induction. Apoptosis induction 
by SGS-transfected cells was measured in flow cytometry in MiaPaCa-
2 cells (A) and AsPC-1 cells (B) (Control 1 = untreated cells; control 2 = 
cells treated with non-sense siRNA). Caspase activation 72 h after trans-
fection in MiaPaCa-2 cells (C) and AsPC-1 cells (D) (Control 1 = untreat-
ed cells; control 2 = cells treated with non-sense siRNA). Examples of 
the FACS analysis of MiaPACa-2 (left) and AsPC-1 (right). Apoptotic cells 
are displayed in the upper and lower right quadrants (E).
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Figure 1 Gene-silencing of Bcl-2, Survivin and XIAP. Western blot 
showed efficient silencing in transfected MiaPaCa-2 (A) and AsPC-1 
cells (B). 50,000 cells/well were single-transfected with carrier solution 
(lane 1) and siRNA against Luciferase (lane 2) as control. SGS, lowST and 
ST all effectively silenced the three target genes (lane 3-5). Efficient 
knock-down was also shown in the lowST group by RT-PCR in Mi-
aPaCa-2 (C) and AsPC-1 cells (D). White bars show controls, grey bars 
signify transfected cells. All samples were normalized to β-Actin as a 
house-keeping gene. SGS = Simultaneous gene silencing; lowST = 
Low dose siRNA transfection; ST = Standard dose siRNA transfection.
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pathway [8,23,24]. Based on the concept of apoptotic
thresholds [9], we hypothesized that there might be a
benefit in hitting multiple target genes at the same time
rather than individual genes to achieve an effect on tumor
survival. To test our hypothesis, we required candidate
genes to be upregulated, synergistic, anti-apoptotic mem-
bers of the cell death pathway.
The literature search identified different upregulated
anti-apoptotic genes at the protein level in pancreatic car-
cinoma compared to normal tissue. XIAP, Survivin and
Bcl-2 showed all required characteristics, like upregula-
tion at the protein level and anti-apoptotic action [11,13].
Furthermore, all genes are members of the intrinsic path-
way, which has special importance in pancreatic carci-
noma [8,25].
SGS resulted in a statistically significant activation of
apoptosis in tumor cells as determined by flow cytometry
and caspase activation. None of the low-dose single
transfections (lowST), which used the same dose of target
siRNA, showed comparable effects on the phenotype of
apoptosis resistance, although some effects were statisti-
cally significant.
In standard-dose single transfected (ST) cells, XIAP as
well as Survivin showed apoptosis induction, but no
group reached the effect achieved in the SGS group.
In AsPC-1 cells, the number of apoptotic cells in the ST
group as measured by FACS analysis was not directly pro-
portional to activation of caspases although there was a
trend towards higher activation of caspases in the XIAP
and Survivin ST group (Figure 2B and 2D). However, to
our knowledge the relation between amount of activated
caspases and extent of apoptosis induction is not neces-
sarily linear and the trend towards higher activation in
the Survivin group might be sufficient to result in the
measured number of apoptotic cells. Furthermore, other
effector caspases which were not measured by our assay
might be involved in apoptosis induction in AsPc-1 cells.
Although simultaneous silencing of the candidate genes
was carried out with low dose transfection for each of the
target genes we saw a significant effect on apoptosis
induction. Contrary, the single transfections with lowST
only resulted in subliminal effects on apoptosis induction
(Figure 3).
This effect of SGS might be due to a reduction in the
anti-apoptotic buffering capacity by summation of sub-
threshold effects on the different, redundant control
mechanisms. Our experiment therefore supports the
model of an apoptotic threshold determined by the "net
difference between its activity and opposing compensa-
tory signals" [9]. This concept might be interesting for the
design of future therapies. By choosing appropriate target
genes it could be possible to selectively target pancreatic
cancer cells while preserving normal tissue.
Another interesting aspect of our study is, that the sin-
gle members do display a different order of precedence in
their anti-apoptotic function. Although previous studies
have shown important functions of all three genes in pan-
creatic cancer cells, the direct comparison shows that
IAPs might have a more prominent position in apoptosis
resistance in pancreatic cancer than Bcl-2.
Conclusions
Pancreatic cancer shows a distinct apoptosis resistance
which is due to numerous dysregulations within the cell
death pathway. In the present study we performed a sub-
Table 2: Effects of transfections on apoptosis induction
Target gene MiaPaCa-2 AsPC-1
mean (S.E.) mean (S.E.)
Control Annexin V 3.73 (± 0.5481) 2.23 (± 0.2232)
Caspase 2.15 (± 0.2665) 1.17 (± 0.3060)
Viable Cells 1.65 (± 0.2651) 1.25 (± 0.1784)
SGS Annexin V 12.81 (± 2.0870) 4.49 (± 0.2966)
Caspase 9.96 (± 1.7829) 9.90 (± 1.9189)
Viable Cells 6.70 (± 2.2837) 4.75 (± 0.9908)
XIAP (low ST) Annexin V 3.96 (± 0.6850) 2.34 (± 0.1797)
Caspase 2.41 (± 0.5015) 2.24 (± 1.0513)
Viable Cells 2.42 (± 1.0029) 1.20 (± 0.1452)
Survivin (low ST) Annexin V 5.81 (± 1.0148) 3.17 (± 0.1986)
Caspase 3.77 (± 0.5577) 2.77 (± 0.8111)
Viable Cells 4.02 (± 0.8603) 2.18 (± 0.1375)
Bcl-2 (low ST) Annexin V 3.40 (± 0.4986) 2.36 (± 0.1309)
Caspase 1.88 (± 0.2001) 1.56 (± 0.4392)
Viable Cells 2.27 (± 0.6989) 1.25 (± 0.1200)
XIAP (ST) Annexin V 4.76 (± 0.7350) 3.19 (± 0.1122)
Caspase 7.00 (± 0.3533) 2.55 (± 0.4072)
Viable Cells 2.59 (± 0.7848) 1.87 (± 2.3098)
Survivin (ST) Annexin V 7.77 (± 1.8167) 3.94 (± 0.2719)
Caspase 8.40 (± 3.1037) 3.27 (± 0.9557)
Viable Cells 3.40 (± 0.7485) 5.23 (± 2.3098)
Bcl-2 (ST) Annexin V 3.51 (± 0.5311) 2.84 (± 0.1863)
Caspase 2.94 (± 0.8894) 2.53 (± 1.1196)
Viable Cells 1.49 (± 0.4988) 1.28 (± 0.1331)
Apoptosis induction was analyzed by Annexin V positivity, caspase 
activation and viable cell count. All results are normalized to non-
treated cells. Viable cell counts are depicted in inverse ratios for 
better comparison. Significant results are marked in bold.Rückert et al. BMC Cancer 2010, 10:379
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liminal silencing of different anti-apoptotic target genes
simultaneously, which had a significant impact on apop-
tosis induction in pancreatic cancer cells. Thus, we give
further evidence for the concept of an anti-apoptotic
buffering capacity of pancreatic cancer cells.
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Figure 3 Kiviat Diagram of SGS action in pancreatic cell lines. SGS 
induced apoptosis in both cell lines measured either by Annexin V 
staining or by caspase activity. SGS also reduced the number of viable 
cells in both cell lines. For better visualization, we show the inverse ra-
tio of the cell count. In each assay, SGS generated the highest signals 
(data were taken from table 2).
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